logo-loader
RNS
viewSyncona Limited

Notice of Results

/**/ link{ color: blue }visited{ color: #954F72 } .ad{size:595.3pt 841.9pt;margin:2.0cm 2.0cm 2.0cm 2.0cm;}div.ad{}p.bc{margin:0cm;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Times New Roman","serif";margin-right:3.4pt}span.ba{font-size:10.0pt}p.bd{margin:0cm;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Times New Roman","serif";margin-right: 3.4pt; text-align: center}p.be{margin:0cm;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Times New Roman","serif";margin-right:3.4pt;text-autospace:none}span.ax{font-size:10.0pt;font-family:"Arial","sans-serif";color:black}p.bf{margin:0cm;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Times New Roman","serif";font-weight: bold; margin-right: 3.4pt; text-autospace: none}p.bg{margin:0cm;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Times New Roman","serif";font-weight: bold; margin-right: 3.4pt; text-align: center; text-autospace: none}span.au{font-size:10.0pt;font-family:"Arial","sans-serif"; color:black} p.bh{margin:0cm;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Times New Roman","serif";text-autospace:none}span.as{font-size:10.0pt; font-family:"Arial","sans-serif"}span.aq{font-size:10.0pt;font-family:"Arial","sans-serif"}table.bi{margin-left:-5.4pt;border-collapse:collapse}td.ap{width:230.15pt;padding:0cm 5.4pt 0cm 5.4pt}td.ao{width:214.35pt;padding:0cm 5.4pt 0cm 5.4pt}p.bj{margin-right:0cm;margin-left:0cm;font-size:12.0pt;font-family:"Times New Roman","serif";margin-top: 0cm; text-align: center}span.bk{color: #212721; font-family: "Arial","sans-serif"; font-size: 10.0pt; font-weight: bold}p.bl{margin-right:0cm;margin-left:0cm;font-size:12.0pt;font-family:"Times New Roman","serif";margin-top:0cm;text-align:justify}span.bm{color: #212721; font-family: "Arial","sans-serif"; font-size: 10.0pt; font-weight: bold} p.bn{margin-right:0cm;margin-left:0cm;font-size:12.0pt;font-family:"Times New Roman","serif";margin-top:0cm;text-align:justify}span.bo{font-size:10.0pt;font-family:"Arial","sans-serif";color:#212721}span.bp{font-size:10.0pt;font-family:"Arial","sans-serif";color:#212721}span.bq{color: #212721; font-family: "Arial","sans-serif"; font-size: 10.0pt; font-weight: bold}span.ai{font-size: 11.0pt;font-family:"Calibri","sans-serif";color:#212721}p.br{margin-right:0cm;margin-left:0cm;font-size:12.0pt;font-family:"Times New Roman","serif";margin-top:6.0pt;text-align:justify}p.bs{margin-right:0cm;margin-left:0cm;font-size:12.0pt;font-family:"Times New Roman","serif";margin-top:11.0pt;text-align:justify}span.bt{font-size:10.0pt;font-family:"Arial","sans-serif";color:#212721}p.bu{margin-right:0cm;margin-left:0cm;font-size:12.0pt;font-family:"Times New Roman","serif";margin-top:6.0pt;text-align:justify;background:white}span.af{font-size:11.0pt;font-family:"Calibri","sans-serif";color:#212721} /**/
RNS Number : 9463S
Syncona Limited
11 November 2019
 

 

 

 

 

11 November 2019

 

 

Notice of Interim Results

 

 

Syncona Ltd, a leading healthcare company focused on founding, building and funding global leaders in life sciences, expects to announce its interim financial results for the six months ended 30 September 2019 on Thursday 21 November 2019.

 

A presentation for analysts will take place at 9.00am GMT and a webcast of the presentation will be available on the Company's website at https://www.synconaltd.com/ or https://webcast.openbriefing.com/syncona-interim2019/

 

To join via conference call, please dial:

 

United Kingdom:

0800 640 6441

United Kingdom (Local):

020 3936 2999

All other locations:

+44 20 3936 2999

Access code:   

379204

                       

 

                       

 

[ENDS]

Enquiries

Syncona Ltd

Siobhan Weaver / Annabel Clay 

Tel: +44 (0) 20 3981 7940

 

 FTI Consulting

Brett Pollard / Ben Atwell / Natalie Garland-Collins

Tel: +44 (0) 20 3727 1000

 

About Syncona

Syncona is a leading FTSE250 healthcare company focused on founding, building and funding global leaders in life science. Our vision is to deliver transformational treatments to patients in truly innovative areas of healthcare while generating superior returns for shareholders.

We seek to partner with the best, brightest and most ambitious minds in science to build globally competitive businesses.

We take a long-term view, underpinned by a deep pool of capital, and are established leaders in gene and cell therapy. We focus on delivering dramatic efficacy for patients in areas of high unmet need.

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
 
END
 
 
NORCKDDQFBDKDDD

Quick facts: Syncona Limited

Price: 218

Market: ISE
Market Cap: £1.44 billion
Follow

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE